Award Timing Predetermined Award Timing Predetermined [Flag] Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Implementation of New Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Schedule of Fair Value, by Balance Sheet Grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Fair value of CVR liability Business Combination, Consideration Transferred, Liabilities Incurred Position [Axis] Position [Axis] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Measurement Basis [Axis] Measurement Basis [Axis] Basic (in dollars per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Commercial Paper Commercial Paper [Member] Total (approximates replacement cost) Inventory, Gross Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Revenue Revenue from Contract with Customer [Text Block] Schedule of Collaborative Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Inventory Disclosure [Abstract] Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Adjustment to Compensation, Amount Adjustment to Compensation Amount Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Employee Stock Option Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Prepaid taxes Prepaid Taxes Total equity Beginning balance Ending balance Equity, Attributable to Parent Insider Trading Policies and Procedures [Line Items] Hedging Designation [Domain] Hedging Designation [Domain] Current Assets Assets, Current [Abstract] Total liabilities and equity Liabilities and Equity Retirement Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Risk Management and Related Financial Instruments Concentration Risk, Credit Risk, Policy [Policy Text Block] Available-for-Sale Securities Available-for-Sale Securities [Member] Cash and cash equivalents at January 1 Cash and Cash Equivalents at March 31 Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Liabilities and Equity Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Expenditures for long-lived assets Segment, Expenditure, Addition to Long-Lived Assets Acquisitions Asset Acquisition [Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Purchases of noncurrent investments Payments to Acquire Other Investments Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Acquisitions Business Combination [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Other noncurrent liabilities Other Liabilities, Noncurrent Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Name Measure Name Ventyx Biosciences, Inc Ventyx Biosciences, Inc [Member] Ventyx Biosciences, Inc Long-term income taxes payable Accrued Income Taxes, Noncurrent Trulicity Trulicity [Member] Trulicity [Member] Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] Litigation Case Type [Domain] Litigation Case [Domain] Award Type Award Type [Axis] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Long-term debt, including current portion Long-Term Debt Potential achievements Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Terms or rights and obligations under collaborative arrangements. Legal Entity [Axis] Legal Entity [Axis] Ebglyss Ebglyss [Member] Ebglyss Total assets Assets Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Cost Portion at Other than Fair Value Measurement [Member] Trading Symbol Trading Symbol Business Combinations Business Combination [Policy Text Block] Geographical [Domain] Geographical [Domain] Entity Address, City or Town Entity Address, City or Town Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Cash Flows from Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Less: Less Significant Expenses [Abstract] Less Significant Expenses Other segment items Segment Reporting, Other Segment Item, Amount Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Inventories Inventory Disclosure [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net change in short-term borrowings Proceeds from (Repayments of) Short-Term Debt Schedule of Change in Accounting Estimate [Table] Change in Accounting Estimate [Table] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Cash paid, net of cash acquired Business Combination, Consideration Transferred Entity Emerging Growth Company Entity Emerging Growth Company Research and development Research and Development Expense (Excluding Acquired in Process Cost) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Equity method investments Equity Method Investments Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination [Domain] Business Combination [Domain] Document Information [Table] Document Information [Table] PEO PEO [Member] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] U.S. UNITED STATES Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Retained Earnings Retained Earnings [Member] Taltz Taltz [Member] Taltz [Member] December 2024 Share Repurchase Program December 2024 Share Repurchase Program [Member] December 2024 Share Repurchase Program Early-stage Early-Stage [Member] Early-Stage Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Income Statement [Abstract] Income Statement [Abstract] Income taxes Income Tax Expense (Benefit) Verzenio Verzenio [Member] Verzenio [Member] Document Information [Line Items] Document Information [Line Items] Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Designated as accounting hedges Designated as Hedging Instrument [Member] Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Business Combination [Table] Business Combination [Table] Subsidiary or Equity Method Investee, Sale of Stock [Table] Subsidiary or Equity Method Investee, Sale of Stock [Table] Derivative, notional amount Derivative, Notional Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Cash Flows from Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net Cash Provided by Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Investments Noncurrent investments Long-Term Investments Other oncology Other Oncology [Member] Other Oncology [Member] Goodwill Goodwill Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount 0.500% Notes due 2033 0.500% Notes Due 2033 [Member] 0.500% Notes Due 2033 [Member] Equity Components [Axis] Equity Components [Axis] Outside U.S. Non-US [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Late-stage Late-Stage [Member] Late-Stage Employee benefit trust Common Stock, Shares Held in Employee Trust Net product revenue Product [Member] Number of reportable segments Number of Reportable Segments Other Performance Measure, Amount Other Performance Measure, Amount Short-term borrowings and current maturities of long-term debt Debt, Current Entity Address, State or Province Entity Address, State or Province Total current liabilities Liabilities, Current Derivative Instrument [Axis] Derivative Instrument [Axis] Individual: Individual [Axis] Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Cash paid for acquisitions, net of cash acquired Other Payments to Acquire Businesses Other current assets Other Assets, Current Additional paid-in capital Additional Paid in Capital, Common Stock Effect of Change in Accounting Estimate, Type [Axis] Effect of Change in Accounting Estimate, Type [Axis] Entity [Domain] Entity [Domain] Net Cash Used for Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Number of potentially responsible parties Loss Contingency, Number Of Potentially Responsible Parties Loss Contingency, Number Of Potentially Responsible Parties Document Fiscal Year Focus Document Fiscal Year Focus Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Repayments of long-term debt Repayments of Long-Term Debt Effective income tax rates, percentage Effective Income Tax Rate Reconciliation, Percent Entity Interactive Data Current Entity Interactive Data Current Carrying Amount Reported Value Measurement [Member] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Equity [Abstract] Equity [Abstract] Derivatives Derivatives, Policy [Policy Text Block] Segment Information Segment Reporting Disclosure [Text Block] Not designated as accounting hedges Not Designated as Hedging Instrument [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Other securities Other Debt Obligations [Member] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Short-term commercial paper borrowings Commercial Paper Marketing, selling, and administrative Selling, General and Administrative Expense Deferred tax assets Deferred Income Tax Assets, Net Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Other noncurrent assets Other Assets, Noncurrent Costs, expenses, and other Cost Of Sales, Operating Expenses, And Other-net Cost Of Sales, Operating Expenses, And Other-net Entity Central Index Key Entity Central Index Key PEO Name PEO Name Immunology Immunology [Member] Immunology [Member] Revenue Revenue Revenues Recognized in other–net, (income) expense Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Finished products Inventory, Finished Goods, Gross Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Zepbound Zepbound [Member] Zepbound Schedule of Components of Equity Schedule of Stockholders Equity [Table Text Block] Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Class of Stock [Domain] Class of Stock [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Europe Europe [Member] Other investing activities, net Payment for (Proceeds from) Other Investing Activity Other operating activities, net Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Purchases of common stock (in shares) Stock Repurchased and Retired During Period, Shares Purchase Long [Member] Acquired in-process research and development (IPR&D) Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill Cash Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Assets Assets [Abstract] Long-term debt Long-Term Debt, Excluding Current Maturities Other cardiometabolic health Other Cardiometabolic Health [Member] Other Cardiometabolic Health Underlying Security Market Price Change Underlying Security Market Price Change, Percent Financial Instruments Fair Value Disclosures [Text Block] Business Combination [Line Items] Business Combination [Line Items] Other current liabilities Derivative Liability, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Work in process Inventory, Work in Process, Gross Asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Reportable Segment Reportable Segment [Member] Reportable Segment Other Other Accumulated Comprehensive Income Loss Attributable To Parent [Member] Accumulated Comprehensive Income Loss Other Quarterly Report Document Quarterly Report Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Non-PEO NEO Non-PEO NEO [Member] Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Ilya Yuffa [Member] Ilya Yuffa Position [Domain] Position [Domain] Other financing activities, net Proceeds from (Payment for) Other Financing Activity Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Schedule of Fair Value Information, Liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Name Trading Arrangement, Individual Name All Award Types Award Type [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Fair Value Measurements Using Estimate of Fair Value Measurement [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] China CHINA MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Contingent value right, additional price per share (in dollars per share) Business Acquisition, Contingent Value Right, Additional Price Per Share Business Acquisition, Contingent Value Right, Additional Price Per Share Asset Acquisition [Line Items] Asset Acquisition [Line Items] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Financial Instruments [Domain] Financial Instruments [Domain] Litigation Case [Axis] Litigation Case [Axis] Segments [Domain] Segments [Domain] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Inventories Inventories Inventory, Net Noncurrent Assets Assets, Noncurrent [Abstract] Company Selected Measure Name Company Selected Measure Name Fair Value Measurement [Domain] Fair Value Measurement [Domain] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Common stock Common Stock, Value, Issued Contingencies Commitments and Contingencies Disclosure [Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments and Contingencies Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Cash acquired Cash Acquired from Acquisition Derivative [Table] Derivative [Table] Business Combination [Axis] Business Combination [Axis] Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Transition Report Document Transition Report 1.700% Notes due 2049 1.700% Notes Due 2049 [Member] 1.700% Notes due 2049 [Member] Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Income Taxes Income Tax Disclosure [Text Block] Common Stock (no par value) Common Class A [Member] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Hedging Designation [Axis] Hedging Designation [Axis] Schedule of Effects of Significant Risk-Management Programs Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Other immunology Other Immunology [Member] Other Immunology [Member] Document Type Document Type Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Name Outstanding Recovery, Individual Name Loss Contingencies [Table] Loss Contingencies [Table] Product and Service [Axis] Product and Service [Axis] Derivative Contract [Domain] Derivative Contract [Domain] 1.625% Notes due 2043 1.625% Notes Due 2043 [Member] 1.625% Notes Due 2043 All Individuals All Individuals [Member] Effect of Change in Accounting Estimate, Type [Domain] Effect of Change in Accounting Estimate, Type [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Name Forgone Recovery, Individual Name Total current assets Assets, Current Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Purchases of property and equipment Payments to Acquire Other Property, Plant, and Equipment Other receivables Other Receivables, Net, Current Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Average remaining maturity of foreign currency derivatives Average Remaining Maturity of Foreign Currency Derivatives Purchases of in-process research and development Payments to Acquire in Process Research and Development Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Schedule of Significant Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Current Liabilities Liabilities, Current [Abstract] Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Geographical [Axis] Geographical [Axis] Rest of world Rest Of World [Member] Rest Of World Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Business acquisition, share price (in dollars per share) Business Combination, Price Per Share Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Diluted (in dollars per share) Earnings Per Share, Diluted Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Title of 12(b) Security Title of 12(b) Security Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] 1.125% Notes due 2051 1.125% Notes Due 2051 [Member] 1.125% Notes Due 2051 Earnings per share: Earnings Per Share [Abstract] 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] Other–net, (income) expense Nonoperating Income (Expense) Asset Acquisition [Table] Asset Acquisition [Table] Short-term investments Debt Securities, Available-for-Sale, Current Purchases of common stock Stock Repurchased and Retired During Period, Value Foreign Currency-Denominated Notes Foreign Currency-Denominated Notes [Member] Foreign Currency-Denominated Notes Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] 0.625% Notes due 2031 0.625% Notes Due 2031 [Member] 0.625% Notes due 2031 [Member] Other Stockholders' Equity, Other Marketable equity securities Equity Securities, FV-NI, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Employee compensation Employee-related Liabilities, Current Acquired in-process research and development Acquired in-process research and development Acquired in-process research and development Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Legal settlement payment Payments for Legal Settlements Equity Equity [Text Block] Number of sites jointly and severally liable for cleanup (fewer than) Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Net income Net income Net income Net Income (Loss) Attributable to Parent Subsidiary or Equity Method Investee [Line Items] Subsidiary or Equity Method Investee [Line Items] Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Expiration Date Trading Arrangement Expiration Date Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Less: Business Combination, Cash Acquired [Abstract] Business Combination, Cash Acquired Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Property and equipment, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Purchases of common stock Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Contingent value right, additional price per share, aggregate amount Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Entity Current Reporting Status Entity Current Reporting Status 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Sales rebates and discounts Sales Rebates And Discounts Sales Rebates And Discounts Derivative [Line Items] Derivative [Line Items] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Increase to last-in, first-out cost Inventory, LIFO Reserve Japan JAPAN Retained earnings Retained Earnings (Accumulated Deficit) Verve Therapeutics, Inc. Verve Therapeutics, Inc. [Member] Verve Therapeutics, Inc. Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Foreign Exchange Forward Foreign Exchange Forward [Member] Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Current Fiscal Year End Date Current Fiscal Year End Date Class of Stock [Axis] Class of Stock [Axis] Other equity Other Additional Capital Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Israel ISRAEL Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Cash Flows from Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Boehringer Ingelheim Boehringer Ingelheim [Member] Boehringer Ingelheim Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Acquisition date fair value of consideration transferred Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Financial Information Regularly Reviewed by the CODM Segment Reporting Information, Profit (Loss) [Abstract] Basis of Presentation and Implementation of New Financial Accounting Standards Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] All Adjustments to Compensation All Adjustments to Compensation [Member] Consideration transferred, number of contingent value rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Amendment Flag Amendment Flag 1.375% Notes due 2061 1.375% Notes Due 2061 [Member] 1.375% Notes Due 2061 Termination Date Trading Arrangement Termination Date Net Cash (Used for) Provided by Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Noncurrent investments Debt Securities, Available-for-Sale, Noncurrent Jardiance Jardiance Jardiance [Member] Jardiance [Member] Schedule of Fair Value Information, Assets Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock repurchase program, remaining authorized amount Share Repurchase Program, Remaining Authorized, Amount Cost of sales Cost of Product and Service Sold Patrik Jonsson [Member] Patrik Jonsson Segment Reporting [Abstract] Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Costs, expenses, and other: Costs and Expenses [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Sell Short [Member] Roche Roche [Member] Roche [Member] Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Dividends paid Payments of Dividends Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Other receivables Derivative Asset, Current Total Shareholder Return Amount Total Shareholder Return Amount Loss Contingencies [Line Items] Loss Contingencies [Line Items] Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Raw materials and supplies Inventory, Raw Materials, Gross Other Product and Service, Other [Member] Total noncurrent liabilities Liabilities, Noncurrent Number of class action petitions Loss Contingency, Number Of Class Action Petitions Loss Contingency, Number Of Class Action Petitions Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Anat Hakim [Member] Anat Hakim Prepaid expenses Prepaid Expense, Current Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other current liabilities Other Liabilities, Current Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Fair value of equity interest in Verve held before the business combination Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Fair Value Mounjaro Mounjaro [Member] Mounjaro [Member] Cardiometabolic Health Cardiometabolic Health [Member] Cardiometabolic Health Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Common Stock Common Stock [Member] Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Net decrease in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation